Cardinal Health (CAH) 10-Q 2 Nov 16 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Sep. 30, 2016	Oct. 27, 2016
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Trading Symbol	cah
Entity Registrant Name	CARDINAL HEALTH INC
Entity Central Index Key	721,371
Current Fiscal Year End Date	--06-30
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		320,063,302

Consolidated Statements of Earn

Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Revenue	$ 32,039	$ 28,055
Cost of products sold	30,449	26,476
Gross margin	1,590	1,579
Operating expenses:
Distribution, selling, general, and administrative expenses	920	842
Restructuring and employee severance	9	12
Amortization and other acquisition-related costs	122	105
Impairments and (gain)/loss on disposal of assets, net	3	0
Litigation (recoveries)/charges, net	1	0
Operating earnings	535	620
Other (income)/expense, net	(3)	8
Interest expense, net	44	44
Earnings before income taxes	494	568
Provision for income taxes	184	184
Net earnings	310	384
Net earnings attributable to noncontrolling interests	1	1
Net earnings attributable to Cardinal Health, Inc.	$ 309	$ 383
Earnings per common share attributable to Cardinal Health, Inc.:
Basic (in shares)	$ 0.97	$ 1.17
Diluted (in shares)	$ 0.96	$ 1.15
Weighted-average number of common shares outstanding:
Basic (in shares)	320	328
Diluted (in shares)	322	331
Cash dividends declared per common share	$ 0.4489	$ 0.3870

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Statement of Comprehensive Income [Abstract]
Net earnings	$ 310	$ 384
Other comprehensive income/(loss):
Foreign currency translation adjustments and other	(1)	(44)
Net unrealized gain/(loss) on derivative instruments, net of tax	1	(1)
Total other comprehensive income/(loss), net of tax	0	(45)
Total comprehensive income	310	339
Less: comprehensive income attributable to noncontrolling interests	(1)	(1)
Total comprehensive income attributable to Cardinal Health, Inc.	$ 309	$ 338

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2016	Jun. 30, 2016
Current assets:
Cash and equivalents	$ 2,001	$ 2,356
Trade receivables, net	7,708	7,405
Inventories, net	10,917	10,615
Prepaid expenses and other	1,657	1,580
Total current assets	22,283	21,956
Property and equipment, net	1,823	1,796
Goodwill and other intangibles, net	9,427	9,426
Other assets	873	944
Total assets	34,406	34,122
Current liabilities:
Accounts payable	17,597	17,306
Current portion of long-term obligations and other short-term borrowings	616	587
Other accrued liabilities	1,788	1,808
Total current liabilities	20,001	19,701
Long-term obligations, less current portion	4,916	4,952
Deferred income taxes and other liabilities	2,842	2,781
Redeemable noncontrolling interests	116	117
Preferred shares, without par value:
Authorized—500 thousand shares, Issued—none	0	0
Common shares, without par value:
Authorized—755 million shares, Issued—364 million shares at September 30, 2016 and June 30, 2016	2,958	3,010
Retained earnings	6,582	6,419
Common Shares in treasury, at cost: 44 million shares and 42 million shares at September 30, 2016 and June 30 2016, respectively	(2,912)	(2,759)
Accumulated other comprehensive loss	(116)	(116)
Total Cardinal Health, Inc. shareholders' equity	6,512	6,554
Noncontrolling interests	19	17
Total shareholders’ equity	6,531	6,571
Total liabilities, redeemable noncontrolling interests, and shareholders’ equity	$ 34,406	$ 34,122

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - shares	Sep. 30, 2016	Jun. 30, 2016
Statement of Financial Position [Abstract]
Preferred shares, authorized	500,000	500,000
Preferred shares, issued	0	0
Common shares, authorized	755,000,000	755,000,000
Common shares, issued	364,000,000	364,000,000
Common shares in treasury	44,000,000	42,000,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net earnings	$ 310	$ 384
Adjustments to reconcile net earnings to net cash provided by/(used in) operating activities:
Depreciation and amortization	173	137
Impairments and (gain)/loss on disposal of assets, net	3	0
Share-based compensation	23	30
Provision for bad debts	7	17
Change in fair value of contingent consideration obligation	0	(1)
Change in operating assets and liabilities, net of effects from acquisitions:
Increase in trade receivables	(306)	(348)
Increase in inventories	(298)	(495)
Increase in accounts payable	279	425
Other accrued liabilities and operating items, net	(87)	(201)
Net cash provided by/(used in) operating activities	104	(52)
Cash flows from investing activities:
Acquisition of subsidiaries, net of cash acquired	(9)	(1,399)
Additions to property and equipment	(100)	(83)
Purchase of available for sale securities and other investments	(52)	(26)
Proceeds from sale of available-for-sale securities and other investments	34	25
Proceeds from maturities of available-for-sale securities	17	5
Net cash used in investing activities	(110)	(1,478)
Cash flows from financing activities:
Payment of contingent consideration obligation	0	23
Net change in short-term borrowings	25	36
Net purchase of noncontrolling interests	(10)	0
Reduction of long-term obligations	(1)	(4)
Proceeds from interest rate swap terminations	14	0
Net tax withholdings from share-based compensation	(9)	(21)
Excess tax benefits from share-based compensation	30	31
Dividends on common shares	(149)	(131)
Payments for Repurchase of Common Stock	(250)
Treasury Stock, Value, Acquired, Cost Method		0
Net cash used in financing activities	(350)	(112)
Effect of exchange rates changes on cash and equivalents	1	0
Net decrease in cash and equivalents	(355)	(1,642)
Cash and equivalents at beginning of period	2,356	4,616
Cash and equivalents at end of period	$ 2,001	$ 2,974

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	1. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise. Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2017 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2017 . These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2016 (the " 2016 Form 10-K "). Recent Financial Accounting Standards In August 2016, the Financial Accounting Standards Board (the "FASB") issued accounting guidance which clarifies the classification of certain cash receipts and cash payments in the statement of cash flows, including those related to contingent consideration payments made after a business combination, distributions received from equity method investees, debt prepayment or debt extinguishment costs, and proceeds from the settlement of insurance claims. This guidance will be effective for us in the first quarter of fiscal 2019. We are currently evaluating the impact of this standard on our consolidated financial statements. In April 2015, the FASB issued amended accounting guidance that clarifies the circumstances under which a cloud computing customer would account for the arrangement as a license of internal-use software. If it is determined that a software license does not exist in the arrangement, the customer would account for this arrangement as a service contract. We adopted this guidance in the first quarter of fiscal 2017. The adoption of this guidance did not have a material impact on our financial position or results of operations. Also in April 2015, the FASB issued amended accounting guidance related to the presentation of debt issuance costs in the financial statements. This guidance requires an entity to present such costs in the balance sheet as a direct deduction from the related debt rather than as an asset. We adopted this guidance in the first quarter of fiscal 2017. Upon adoption of this guidance, debt issuance costs of $29 million were reclassified from other assets to long-term obligations, less current portion within the condensed consolidated balance sheet. In May 2014, the FASB issued amended accounting guidance related to revenue recognition. This guidance is based on the principle that revenue is recognized in an amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services to customers. The guidance also requires additional disclosure about the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. This amendment will be effective for us in the first quarter of fiscal 2019. We are in the process of assessing any differences between the amended and existing guidance that could impact our consolidated financial statements and continuing to evaluate the options for adoption.

Acquisitions Acquisitions

Acquisitions Acquisitions	3 Months Ended
	Sep. 30, 2016
Business Combinations [Abstract]
Acquisitions	2. Acquisitions Cordis On October 2, 2015 , we acquired the Cordis business from Ethicon, Inc., a wholly-owned subsidiary of Johnson & Johnson, for $1.9 billion using cash on hand and proceeds from our debt offering in June 2015 . The acquisition of Cordis, a global manufacturer and distributor of interventional cardiology devices and endovascular solutions with operations in more than 50 countries, expands our Medical segment's portfolio of self-manufactured products and its geographic scope. We closed the Cordis acquisition in 20 principal countries on October 2, 2015 , and acquired control of, as described in GAAP, and the rights to, the net economic benefit from the entire Cordis business in the remaining countries at that time. Transaction and integration costs associated with the acquisition of Cordis were $14 million and $21 million during the three months ended September 30, 2016 and 2015 , respectively, and are included in amortization and other acquisition-related costs in the condensed consolidated statements of earnings. Fair Value of Assets Acquired and Liabilities Assumed The allocation of the fair value of assets acquired and liabilities assumed for the acquisitions of Cordis, naviHealth Holdings, LLC. ("naviHealth"), and The Harvard Drug Group ("Harvard Drug") were finalized during the three months ended September 30, 2016, resulting in goodwill of $943 million , $334 million , and $634 million , respectively. There were no significant adjustments to the allocation of the fair value of assets acquired and liabilities assumed for the naviHealth and Harvard Drug acquisitions from those disclosed in our fiscal 2016 Form 10-K. We recorded additional goodwill for Cordis of $82 million , substantially all of which was to increase an accrual for assumed pre-acquisition product liability lawsuits. See Note 7 for further discussion of the product liability lawsuits.

Restructuring and Employee Seve

Restructuring and Employee Severance	3 Months Ended
	Sep. 30, 2016
Restructuring Charges [Abstract]
Restructuring and Employee Severance	3. Restructuring and Employee Severance The following table summarizes restructuring and employee severance costs: Three months ended September 30, (in millions) 2016 2015 Employee-related costs (1) $ 7 $ 6 Facility exit and other costs (2) 2 6 Total restructuring and employee severance $ 9 $ 12 (1) Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated and duplicate payroll costs during transition periods. (2) Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services. The following table summarizes activity related to liabilities associated with restructuring and employee severance: (in millions) Employee- Related Costs Facility Exit and Other Costs Total Balance at June 30, 2016 $ 15 $ 1 $ 16 Additions 6 — 6 Payments and other adjustments (4 ) (1 ) (5 ) Balance at September 30, 2016 $ 17 $ — $ 17

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	3 Months Ended
	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	4. Goodwill and Other Intangible Assets Goodwill The following table summarizes the changes in the carrying amount of goodwill by segment and in total: (in millions) Pharmaceutical Medical Total Balance at June 30, 2016 $ 2,919 $ 4,248 $ 7,167 Goodwill acquired, net of purchase price adjustments 9 86 95 Foreign currency translation adjustments and other (2 ) 1 (1 ) Balance at September 30, 2016 $ 2,926 $ 4,335 $ 7,261 Other Intangible Assets The following tables summarize other intangible assets by class at: September 30, 2016 (in millions) Gross Intangible Accumulated Amortization Net Intangible Weighted- Average Remaining Amortization Period (Years) Indefinite-life intangibles: IPR&D, trademarks and other $ 70 $ — $ 70 N/A Total indefinite-life intangibles 70 — 70 N/A Definite-life intangibles: Customer relationships 1,931 793 1,138 9 Trademarks, trade names, and patents 527 156 371 14 Developed technology and other 812 225 587 8 Total definite-life intangibles 3,270 1,174 2,096 10 Total other intangible assets $ 3,340 $ 1,174 $ 2,166 N/A June 30, 2016 (in millions) Gross Intangible Accumulated Amortization Net Intangible Indefinite-life intangibles: IPR&D, trademarks and other $ 72 $ — $ 72 Total indefinite-life intangibles 72 — 72 Definite-life intangibles: Customer relationships 1,946 737 1,209 Trademarks, trade names, and patents 508 140 368 Developed technology and other 808 198 610 Total definite-life intangibles 3,262 1,075 2,187 Total other intangible assets $ 3,334 $ 1,075 $ 2,259 Total amortization of intangible assets was $101 million and $67 million for the three months ended September 30, 2016 and 2015 , respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2017 through 2021 is as follows: $285 million , $350 million , $281 million , $254 million , and $207 million .

Available-for-Sale Securities

Available-for-Sale Securities	3 Months Ended
	Sep. 30, 2016
Investments, Debt and Equity Securities [Abstract]
Available-for-Sale Securities	5. Available-for-Sale Securities We invest in marketable securities, which are classified as available-for-sale and are carried at fair value in the condensed consolidated balance sheets. We held the following investments in marketable securities at fair value at: (in millions) September 30, 2016 June 30, 2016 Current available-for-sale securities: Treasury bills $ — $ 3 International bonds 3 2 Corporate bonds 58 58 U.S. agency bonds 7 6 Asset-backed securities 31 28 International equity securities 2 2 U.S. agency mortgage-backed securities 7 14 Total current available-for-sale securities 108 113 Long-term available-for-sale securities: Treasury bills 29 10 International bonds 3 1 Corporate bonds 32 36 U.S. agency bonds 8 9 Asset-backed securities 8 17 U.S. agency mortgage-backed securities 12 14 Total long-term available-for-sale securities 92 87 Total available-for-sale securities $ 200 $ 200 Gross unrealized gains and losses were immaterial at both September 30, 2016 and June 30, 2016 . During the three months ended September 30, 2016 and 2015 , gross realized gains and losses were immaterial and we did not recognize any other-than-temporary impairments. At September 30, 2016 , the weighted-average effective maturity of our current and long-term investments was approximately 6 months and 17 months , respectively.

Income Taxes

Income Taxes	3 Months Ended
	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	6. Income Taxes Fluctuations in our provision for income taxes as a percentage of pretax earnings (“effective tax rate”) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. During the three months ended September 30, 2016 and 2015 , the effective tax rate was 37.3 percent and 32.3 percent , respectively. The effective tax rate for the three months ended September 30, 2015 included net favorable discrete items of $28 million . At September 30, 2016 and June 30, 2016 , we had $532 million and $527 million of unrecognized tax benefits, respectively. The September 30, 2016 and June 30, 2016 , balances include $358 million and $355 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. At September 30, 2016 and June 30, 2016 , we had $149 million and $145 million , respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for income taxes in the condensed consolidated statements of earnings. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of $175 million , exclusive of penalties and interest. We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2006 through the current fiscal year. We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), which has been acquired by Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $126 million and $172 million at September 30, 2016 and June 30, 2016 , respectively, and is included in other assets in the condensed consolidated balance sheets.

Commitments, Contingent Liabili

Commitments, Contingent Liabilities and Litigation	3 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingent Liabilities and Litigation	7. Commitments, Contingent Liabilities and Litigation Commitments Generic Sourcing Venture with CVS Health Corporation ("CVS Health") In July 2014 , we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years . Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of both companies. Due to the achievement of predetermined milestones, we are required to make quarterly payments of $45.6 million to CVS Health for the remainder of the initial term. Legal Proceedings We become involved from time to time in disputes, litigation, and regulatory matters. We may be named from time to time in qui tam actions, which are initiated by private third parties purporting to act on behalf of federal or state governments and which allege that false claims have been submitted or have been caused to be submitted for payment by the government. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own on behalf of the government. From time to time, we receive subpoenas or requests for information from various government agencies relating to our business or to the business of a customer, supplier, or other industry participant. Most of these matters are resolved without incident; however, such subpoenas or requests can lead to the assertion of claims or the commencement of legal proceedings against us. From time to time, we may determine that products we manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a quality or regulatory issue, we investigate and take appropriate corrective action. Such actions can lead to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, action by regulators, and product liability claims and lawsuits, including class actions. We accrue for contingencies related to disputes, litigation, and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates. With respect to the matters described below, except as otherwise stated, we are unable to estimate a range of reasonably possible loss for matters for which there is no accrual, or additional loss for matters for which we have recorded an accrual, since damages or fines have not been specified or the proceedings are at stages where significant uncertainty exists as to legal or factual issues and as to whether such matters will proceed to trial. We do not believe, based on currently available information, that the outcomes of these matters will have a material adverse effect on our financial position, results of operations, or cash flows. However, the outcome of one or more of these matters could be material to our results of operations for a particular quarterly period. We recognize income from the favorable outcome of litigation when we receive the associated cash or assets. Except as otherwise stated below, we recognize estimated loss contingencies for litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings. DEA Investigation and Related Matters In February 2012, the U.S. Drug Enforcement Administration (the "DEA") issued an order to show cause and immediate suspension of our Lakeland, Florida distribution center's registration to distribute controlled substances, asserting that we failed to maintain required controls against the diversion of controlled substances. In May 2012, we entered into a settlement agreement with the DEA that resolved the administrative aspects of the DEA's action but did not resolve potential liability for civil fines in Florida or elsewhere for the conduct covered by the settlement agreement. In that regard, we are continuing to discuss a settlement with the U.S. Department of Justice. Our total accrual for this matter was $44 million at both September 30, 2016 and June 30, 2016 , which is included in other accrued liabilities in the condensed consolidated balance sheets. State of West Virginia vs. Cardinal Health, Inc. Since June 2012, the West Virginia Attorney General has filed complaints against a number of pharmaceutical wholesale distributors, including us. The complaints, which were filed in the Circuit Court of Boone County, West Virginia, allege, among other things, that the distributors failed to maintain effective controls to guard against diversion of controlled substances in West Virginia, failed to report suspicious orders of controlled substances in accordance with the West Virginia Uniform Controlled Substances Act, and were negligent in distributing controlled substances to pharmacies that serve individuals who abuse controlled substances. The complaints seek, among other things, injunctive and other equitable relief and monetary damages. We are vigorously defending ourselves in this matter. Product Liability Lawsuits As of October 31, 2016, we and our Cordis business have been named as defendants in 31 product liability lawsuits involving claims by approximately 250 plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava (IVC) filter products. These lawsuits seek a variety of remedies, including unspecified monetary damages. We are vigorously defending ourselves in these matters. Based on currently available information, we have recorded an accrual, most of which relates to legal defense costs, as an adjustment to pre-acquisition liabilities assumed in the Cordis acquisition. Refer to Note 2 for further information regarding this adjustment. We do not believe that reasonably possible losses in excess of this accrued amount will be material to our financial statements.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	8. Fair Value Measurements The following tables present the fair values for assets and (liabilities) measured on a recurring basis at: September 30, 2016 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 176 $ — $ — $ 176 Forward contracts (1) — 2 — 2 Available-for-sale securities (2) — 200 — 200 Other investments (3) 109 — — 109 Liabilities: Contingent Consideration (4) — — (21 ) (21 ) June 30, 2016 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 516 $ — $ — $ 516 Forward contracts (1) — 19 — 19 Available-for-sale securities (2) — 200 — 200 Other investments (3) 103 — — 103 Liabilities: Contingent Consideration (4) — — (19 ) (19 ) (1) The fair value of interest rate swaps, foreign currency contracts and commodity contracts is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in the condensed consolidated balance sheets. (2) We invest in marketable securities, which are classified as available-for-sale and are carried at fair value in the condensed consolidated balance sheets. Observable Level 2 inputs such as quoted prices for similar securities, interest rate spreads, yield curves and credit risk are used to determine the fair value. See Note 5 for additional information regarding available-for-sale securities. (3) The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds primarily invest in the equity securities of companies with large market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices. (4) Contingent consideration represents the obligations incurred in connection with acquisitions. We do not deem the fair value of the contingent consideration obligations under any single acquisition to be significant. The estimate of fair value of the contingent consideration obligations requires subjective assumptions to be made regarding future business results, discount rates, discount periods, and probabilities assigned to various potential business result scenarios and was determined using probability assessments with respect to the likelihood of reaching various targets or of achieving certain milestones. The fair value measurement is based on significant inputs unobservable in the market and thus represents a Level 3 measurement. Changes in current expectations of progress could change the probability of achieving the targets within the measurement periods and result in an increase or decrease in the fair value of the contingent consideration obligation. The following table presents those liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3): (in millions) Contingent Consideration Obligation Balance at June 30, 2016 $ 19 Additions from acquisitions 2 Changes in fair value of contingent consideration (1) — Balance at September 30, 2016 $ 21 (1) Amount is included in amortization and other acquisition-related costs in the condensed consolidated statements of earnings.

Financial Instruments

Financial Instruments	3 Months Ended
	Sep. 30, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments	9. Financial Instruments We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to fair value through earnings at the end of each period. Our derivative and hedging programs are consistent with those described in the 2016 Form 10-K. The amount of ineffectiveness associated with these derivative instruments was immaterial for the three months ended September 30, 2016 and 2015 . During the three months ended September 30, 2016 , we entered into forward interest rate swap locks with a total notional amount of $200 million to hedge probable, but not firmly committed, future transactions associated with our debt. During the three months ended September 30, 2016 , we terminated notional amounts of $200 million of pay-floating interest rate swaps. We received net settlement proceeds of $ 14 million related to the pay-floating interest rate swaps terminated during the three months ended September 30, 2016 and the pay-floating interest rate swaps terminated in fiscal 2016, as previously disclosed in our 2016 Form 10-K. These swaps were previously designated as fair value hedges. There was no immediate impact to the condensed consolidated statements of earnings; however, the fair value adjustment to debt is being amortized over the life of the underlying debt as a reduction to interest expense, net in the condensed consolidated statements of earnings. Fair Value of Financial Instruments The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at September 30, 2016 and June 30, 2016 approximate fair value due to their short-term maturities. The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at: (in millions) September 30, 2016 June 30, 2016 Estimated fair value $ 5,884 $ 5,780 Carrying amount 5,532 5,539 The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.

Redeemable Noncontrolling Inter

Redeemable Noncontrolling Interests	3 Months Ended
	Sep. 30, 2016
Temporary Equity [Abstract]
Redeemable Noncontrolling Interests	10. Redeemable Noncontrolling Interests Redeemable noncontrolling interest represents the third parties' share of the net assets of naviHealth. The third-party noncontrolling interest holders hold an option that allows them to sell their noncontrolling interests to us at any time after the two-year anniversary of the closing, or earlier if a trigger event occurs. The terms of the agreement also provide us with the option to acquire any remaining noncontrolling interests at any time after the two-year anniversary of the closing, which is August 26, 2017. Our ownership interest in naviHealth was 82 percent at September 30, 2016 . The reconciliation of the changes in redeemable noncontrolling interests are as follows: (in millions) Redeemable Noncontrolling Interest Balance at June 30, 2016 $ 117 Net earnings attributable to redeemable noncontrolling interests 1 Net purchase of redeemable noncontrolling interests (2 ) Balance at September 30, 2016 $ 116

Shareholders' Equity

Shareholders' Equity	3 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Shareholders' Equity	11. Shareholders' Equity During the three months ended September 30, 2016 , we repurchased 3 million common shares having an aggregate cost of $250 million . The average price paid per common share was $81.37 . During the three months ended September 30, 2015 , we did not repurchase any common shares. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes. Accumulated Other Comprehensive Loss The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total: (in millions) Foreign Currency Translation Adjustments Unrealized Gain/(Loss) on Derivatives, net of tax Accumulated Other Comprehensive Loss Balance at June 30, 2016 $ (123 ) $ 7 $ (116 ) Other comprehensive income/(loss), before reclassifications (1 ) 2 1 Amounts reclassified to earnings — (1 ) (1 ) Other comprehensive income/(loss), net of tax (1 ) 1 — Balance at September 30, 2016 $ (124 ) $ 8 $ (116 ) Activity related to realized and unrealized gains and losses on available-for-sale securities, as described in Note 5 , was immaterial during the three months ended September 30, 2016 .

Earnings Per Share Attributable

Earnings Per Share Attributable to Cardinal Health, Inc.	3 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Earnings Per Share Attributable to Cardinal Health, Inc.	12. Earnings Per Share Attributable to Cardinal Health, Inc. The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.: Three Months Ended September 30, (in millions) 2016 2015 Weighted-average common shares–basic 320 328 Effect of dilutive securities: Employee stock options, restricted share units, and performance share units 2 3 Weighted-average common shares–diluted 322 331 The potentially dilutive employee stock options, restricted share units, and performance share units that were antidilutive for the three months ended September 30, 2016 and 2015 were 3 million and 2 million , respectively.

Segment Information

Segment Information	3 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Segment Information	13. Segment Information Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities. The following table presents revenue for each reportable segment and Corporate: Three Months Ended September 30, (in millions) 2016 2015 Pharmaceutical $ 28,762 $ 25,140 Medical 3,279 2,919 Total segment revenue 32,041 28,059 Corporate (1) (2 ) (4 ) Total revenue $ 32,039 $ 28,055 (1) Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments. We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial, and customer care shared services, human resources, information technology, and legal and compliance. The results attributable to noncontrolling interests are recorded within segment profit. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. We do not allocate the following items to our segments: last-in first-out, or ("LIFO"), inventory charges/(credits); restructuring and employee severance; amortization and other acquisition-related costs; impairments and (gain)/loss on disposal of assets; litigation (recoveries)/charges, net; other income, net; interest expense, net; loss on extinguishment of debt; and provision for income taxes. In addition, certain investment spending, certain portions of enterprise-wide incentive compensation, and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. We encourage our segments and corporate functions to identify investment projects that will promote innovation and provide future returns. As approval decisions for such projects are dependent upon executive management, the expenses for such projects are often retained at Corporate. Investment spending within Corporate was $1 million and $6 million for the three months ended September 30, 2016 and 2015 , respectively. The following table presents segment profit by reportable segment and Corporate: Three Months Ended September 30, (in millions) 2016 2015 Pharmaceutical $ 534 $ 657 Medical 127 101 Total segment profit 661 758 Corporate (126 ) (138 ) Total operating earnings $ 535 $ 620 The following table presents total assets for each reportable segment and Corporate at: (in millions) September 30, June 30, Pharmaceutical $ 21,034 $ 20,662 Medical 10,553 10,236 Corporate 2,819 3,224 Total assets $ 34,406 $ 34,122

Share-Based Compensation

Share-Based Compensation	3 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	14. Share-Based Compensation We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees. The following table provides total share-based compensation expense by type of award: Three Months Ended September 30, (in millions) 2016 2015 Restricted share unit expense $ 17 $ 13 Employee stock option expense 5 5 Performance share unit expense 1 12 Total share-based compensation $ 23 $ 30 The total tax benefit related to share-based compensation was $8 million and $11 million for the three months ended September 30, 2016 and 2015 , respectively. Restricted Share Units Restricted share units granted under the Plans generally vest in equal annual installments over three years . Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards. The following table summarizes all transactions related to restricted share units under the Plans: (in millions, except per share amounts) Restricted Share Units Weighted-Average Grant Date Fair Value per Share Nonvested at June 30, 2016 2 $ 71.73 Granted 1 83.15 Vested (1 ) 68.14 Canceled and forfeited — — Nonvested at September 30, 2016 2 $ 80.22 At September 30, 2016 , the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $121 million , which is expected to be recognized over a weighted-average period of two years . Stock Options Employee stock options granted under the Plans generally vest in equal annual installments over three years and are exercisable for periods ranging from seven to ten years from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date. The following table summarizes all stock option transactions under the Plans: (in millions, except per share amounts) Stock Options Weighted-Average Exercise Price per Common Share Outstanding at June 30, 2016 7 $ 54.09 Granted 2 83.14 Exercised (1 ) 37.83 Canceled and forfeited — — Outstanding at September 30, 2016 8 $ 60.65 Exercisable at September 30, 2016 5 $ 49.96 At September 30, 2016 , the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was $35 million , which is expected to be recognized over a weighted-average period of two years . The following tables provide additional detail related to stock options: (in millions) September 30, 2016 June 30, 2016 Aggregate intrinsic value of outstanding options at period end $ 147 $ 181 Aggregate intrinsic value of exercisable options at period end 145 161 (in years) September 30, 2016 June 30, 2016 Weighted-average remaining contractual life of outstanding options 7 6 Weighted-average remaining contractual life of exercisable options 6 5 Performance Share Units Performance share units vest over a three -year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 200 percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards. The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts): (in millions, except per share amounts) Performance Share Units Weighted-Average Grant Date Fair Value per Share Nonvested at June 30, 2016 0.8 $ 63.96 Granted 0.2 83.19 Vested (1) (0.4 ) 51.49 Canceled and forfeited — — Nonvested at September 30, 2016 0.6 $ 77.72 (1) Vested based on achievement of 170 percent of the target performance goal. At September 30, 2016 , the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $23 million , which is expected to be recognized over a weighted-average period of two years .

Basis of Presentation and Sum21

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise. Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2017 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2017 . These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2016 (the " 2016 Form 10-K ").
Recent Financial Accounting Standards	Recent Financial Accounting Standards In August 2016, the Financial Accounting Standards Board (the "FASB") issued accounting guidance which clarifies the classification of certain cash receipts and cash payments in the statement of cash flows, including those related to contingent consideration payments made after a business combination, distributions received from equity method investees, debt prepayment or debt extinguishment costs, and proceeds from the settlement of insurance claims. This guidance will be effective for us in the first quarter of fiscal 2019. We are currently evaluating the impact of this standard on our consolidated financial statements. In April 2015, the FASB issued amended accounting guidance that clarifies the circumstances under which a cloud computing customer would account for the arrangement as a license of internal-use software. If it is determined that a software license does not exist in the arrangement, the customer would account for this arrangement as a service contract. We adopted this guidance in the first quarter of fiscal 2017. The adoption of this guidance did not have a material impact on our financial position or results of operations. Also in April 2015, the FASB issued amended accounting guidance related to the presentation of debt issuance costs in the financial statements. This guidance requires an entity to present such costs in the balance sheet as a direct deduction from the related debt rather than as an asset. We adopted this guidance in the first quarter of fiscal 2017. Upon adoption of this guidance, debt issuance costs of $29 million were reclassified from other assets to long-term obligations, less current portion within the condensed consolidated balance sheet. In May 2014, the FASB issued amended accounting guidance related to revenue recognition. This guidance is based on the principle that revenue is recognized in an amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services to customers. The guidance also requires additional disclosure about the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. This amendment will be effective for us in the first quarter of fiscal 2019. We are in the process of assessing any differences between the amended and existing guidance that could impact our consolidated financial statements and continuing to evaluate the options for adoption.

Restructuring and Employee Se22

Restructuring and Employee Severance (Tables)	3 Months Ended
	Sep. 30, 2016
Restructuring Charges [Abstract]
Summary of Restructuring and Employee Severance	The following table summarizes restructuring and employee severance costs: Three months ended September 30, (in millions) 2016 2015 Employee-related costs (1) $ 7 $ 6 Facility exit and other costs (2) 2 6 Total restructuring and employee severance $ 9 $ 12 (1) Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated and duplicate payroll costs during transition periods. (2) Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.
Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance	The following table summarizes activity related to liabilities associated with restructuring and employee severance: (in millions) Employee- Related Costs Facility Exit and Other Costs Total Balance at June 30, 2016 $ 15 $ 1 $ 16 Additions 6 — 6 Payments and other adjustments (4 ) (1 ) (5 ) Balance at September 30, 2016 $ 17 $ — $ 17

Goodwill and Other Intangible23

Goodwill and Other Intangible Assets (Tables)	3 Months Ended
	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill by Reportable Segment	The following table summarizes the changes in the carrying amount of goodwill by segment and in total: (in millions) Pharmaceutical Medical Total Balance at June 30, 2016 $ 2,919 $ 4,248 $ 7,167 Goodwill acquired, net of purchase price adjustments 9 86 95 Foreign currency translation adjustments and other (2 ) 1 (1 ) Balance at September 30, 2016 $ 2,926 $ 4,335 $ 7,261
Schedule of Finite-Lived Intangible Assets	The following tables summarize other intangible assets by class at: September 30, 2016 (in millions) Gross Intangible Accumulated Amortization Net Intangible Weighted- Average Remaining Amortization Period (Years) Indefinite-life intangibles: IPR&D, trademarks and other $ 70 $ — $ 70 N/A Total indefinite-life intangibles 70 — 70 N/A Definite-life intangibles: Customer relationships 1,931 793 1,138 9 Trademarks, trade names, and patents 527 156 371 14 Developed technology and other 812 225 587 8 Total definite-life intangibles 3,270 1,174 2,096 10 Total other intangible assets $ 3,340 $ 1,174 $ 2,166 N/A June 30, 2016 (in millions) Gross Intangible Accumulated Amortization Net Intangible Indefinite-life intangibles: IPR&D, trademarks and other $ 72 $ — $ 72 Total indefinite-life intangibles 72 — 72 Definite-life intangibles: Customer relationships 1,946 737 1,209 Trademarks, trade names, and patents 508 140 368 Developed technology and other 808 198 610 Total definite-life intangibles 3,262 1,075 2,187 Total other intangible assets $ 3,334 $ 1,075 $ 2,259
Schedule of Indefinite-Lived Intangible Assets	The following tables summarize other intangible assets by class at: September 30, 2016 (in millions) Gross Intangible Accumulated Amortization Net Intangible Weighted- Average Remaining Amortization Period (Years) Indefinite-life intangibles: IPR&D, trademarks and other $ 70 $ — $ 70 N/A Total indefinite-life intangibles 70 — 70 N/A Definite-life intangibles: Customer relationships 1,931 793 1,138 9 Trademarks, trade names, and patents 527 156 371 14 Developed technology and other 812 225 587 8 Total definite-life intangibles 3,270 1,174 2,096 10 Total other intangible assets $ 3,340 $ 1,174 $ 2,166 N/A June 30, 2016 (in millions) Gross Intangible Accumulated Amortization Net Intangible Indefinite-life intangibles: IPR&D, trademarks and other $ 72 $ — $ 72 Total indefinite-life intangibles 72 — 72 Definite-life intangibles: Customer relationships 1,946 737 1,209 Trademarks, trade names, and patents 508 140 368 Developed technology and other 808 198 610 Total definite-life intangibles 3,262 1,075 2,187 Total other intangible assets $ 3,334 $ 1,075 $ 2,259

Available-for-Sale Securities (

Available-for-Sale Securities (Tables)	3 Months Ended
	Sep. 30, 2016
Investments, Debt and Equity Securities [Abstract]
Available-for-sale Securities	We held the following investments in marketable securities at fair value at: (in millions) September 30, 2016 June 30, 2016 Current available-for-sale securities: Treasury bills $ — $ 3 International bonds 3 2 Corporate bonds 58 58 U.S. agency bonds 7 6 Asset-backed securities 31 28 International equity securities 2 2 U.S. agency mortgage-backed securities 7 14 Total current available-for-sale securities 108 113 Long-term available-for-sale securities: Treasury bills 29 10 International bonds 3 1 Corporate bonds 32 36 U.S. agency bonds 8 9 Asset-backed securities 8 17 U.S. agency mortgage-backed securities 12 14 Total long-term available-for-sale securities 92 87 Total available-for-sale securities $ 200 $ 200

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables present the fair values for assets and (liabilities) measured on a recurring basis at: September 30, 2016 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 176 $ — $ — $ 176 Forward contracts (1) — 2 — 2 Available-for-sale securities (2) — 200 — 200 Other investments (3) 109 — — 109 Liabilities: Contingent Consideration (4) — — (21 ) (21 ) June 30, 2016 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 516 $ — $ — $ 516 Forward contracts (1) — 19 — 19 Available-for-sale securities (2) — 200 — 200 Other investments (3) 103 — — 103 Liabilities: Contingent Consideration (4) — — (19 ) (19 ) (1) The fair value of interest rate swaps, foreign currency contracts and commodity contracts is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in the condensed consolidated balance sheets. (2) We invest in marketable securities, which are classified as available-for-sale and are carried at fair value in the condensed consolidated balance sheets. Observable Level 2 inputs such as quoted prices for similar securities, interest rate spreads, yield curves and credit risk are used to determine the fair value. See Note 5 for additional information regarding available-for-sale securities. (3) The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds primarily invest in the equity securities of companies with large market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices. (4) Contingent consideration represents the obligations incurred in connection with acquisitions. We do not deem the fair value of the contingent consideration obligations under any single acquisition to be significant. The estimate of fair value of the contingent consideration obligations requires subjective assumptions to be made regarding future business results, discount rates, discount periods, and probabilities assigned to various potential business result scenarios and was determined using probability assessments with respect to the likelihood of reaching various targets or of achieving certain milestones. The fair value measurement is based on significant inputs unobservable in the market and thus represents a Level 3 measurement. Changes in current expectations of progress could change the probability of achieving the targets within the measurement periods and result in an increase or decrease in the fair value of the contingent consideration obligation.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following table presents those liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3): (in millions) Contingent Consideration Obligation Balance at June 30, 2016 $ 19 Additions from acquisitions 2 Changes in fair value of contingent consideration (1) — Balance at September 30, 2016 $ 21 (1) Amount is included in amortization and other acquisition-related costs in the condensed consolidated statements of earnings.

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended
	Sep. 30, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount	The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at: (in millions) September 30, 2016 June 30, 2016 Estimated fair value $ 5,884 $ 5,780 Carrying amount 5,532 5,539

Redeemable Noncontrolling Int27

Redeemable Noncontrolling Interests (Tables)	3 Months Ended
	Sep. 30, 2016
Temporary Equity [Abstract]
Reconciliation of the Changes in Redeemable Noncontrolling Interests	The reconciliation of the changes in redeemable noncontrolling interests are as follows: (in millions) Redeemable Noncontrolling Interest Balance at June 30, 2016 $ 117 Net earnings attributable to redeemable noncontrolling interests 1 Net purchase of redeemable noncontrolling interests (2 ) Balance at September 30, 2016 $ 116

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	3 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total	Accumulated Other Comprehensive Loss The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total: (in millions) Foreign Currency Translation Adjustments Unrealized Gain/(Loss) on Derivatives, net of tax Accumulated Other Comprehensive Loss Balance at June 30, 2016 $ (123 ) $ 7 $ (116 ) Other comprehensive income/(loss), before reclassifications (1 ) 2 1 Amounts reclassified to earnings — (1 ) (1 ) Other comprehensive income/(loss), net of tax (1 ) 1 — Balance at September 30, 2016 $ (124 ) $ 8 $ (116 )

Earnings Per Share Attributab29

Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)	3 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share	Three Months Ended September 30, (in millions) 2016 2015 Weighted-average common shares–basic 320 328 Effect of dilutive securities: Employee stock options, restricted share units, and performance share units 2 3 Weighted-average common shares–diluted 322 331

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Revenue by Reportable Segment	Three Months Ended September 30, (in millions) 2016 2015 Pharmaceutical $ 28,762 $ 25,140 Medical 3,279 2,919 Total segment revenue 32,041 28,059 Corporate (1) (2 ) (4 ) Total revenue $ 32,039 $ 28,055 (1) Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit by Reportable Segment	Three Months Ended September 30, (in millions) 2016 2015 Pharmaceutical $ 534 $ 657 Medical 127 101 Total segment profit 661 758 Corporate (126 ) (138 ) Total operating earnings $ 535 $ 620
Assets by Reportable Segment	(in millions) September 30, June 30, Pharmaceutical $ 21,034 $ 20,662 Medical 10,553 10,236 Corporate 2,819 3,224 Total assets $ 34,406 $ 34,122

Share-Based Compensation (Table

Share-Based Compensation (Tables)	3 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Total Share-based Compensation Expense by Type of Award	The following table provides total share-based compensation expense by type of award: Three Months Ended September 30, (in millions) 2016 2015 Restricted share unit expense $ 17 $ 13 Employee stock option expense 5 5 Performance share unit expense 1 12 Total share-based compensation $ 23 $ 30
Schedule of Stock Option Transactions Under the Plans	The following table summarizes all stock option transactions under the Plans: (in millions, except per share amounts) Stock Options Weighted-Average Exercise Price per Common Share Outstanding at June 30, 2016 7 $ 54.09 Granted 2 83.14 Exercised (1 ) 37.83 Canceled and forfeited — — Outstanding at September 30, 2016 8 $ 60.65 Exercisable at September 30, 2016 5 $ 49.96
Schedule of Additional Data Related to Stock Option Activity	The following tables provide additional detail related to stock options: (in millions) September 30, 2016 June 30, 2016 Aggregate intrinsic value of outstanding options at period end $ 147 $ 181 Aggregate intrinsic value of exercisable options at period end 145 161 (in years) September 30, 2016 June 30, 2016 Weighted-average remaining contractual life of outstanding options 7 6 Weighted-average remaining contractual life of exercisable options 6 5
Schedule of Transactions Related to Restricted Share Units Under the Plans	The following table summarizes all transactions related to restricted share units under the Plans: (in millions, except per share amounts) Restricted Share Units Weighted-Average Grant Date Fair Value per Share Nonvested at June 30, 2016 2 $ 71.73 Granted 1 83.15 Vested (1 ) 68.14 Canceled and forfeited — — Nonvested at September 30, 2016 2 $ 80.22
Schedule of Transactions Related to Performance Share Units Under the Plans	The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts): (in millions, except per share amounts) Performance Share Units Weighted-Average Grant Date Fair Value per Share Nonvested at June 30, 2016 0.8 $ 63.96 Granted 0.2 83.19 Vested (1) (0.4 ) 51.49 Canceled and forfeited — — Nonvested at September 30, 2016 0.6 $ 77.72 (1) Vested based on achievement of 170 percent of the target performance goal.

Basis of Presentation and Sum32

Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Recent Financial Accounting Standards) (Details) $ in Millions	Sep. 30, 2016USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt Issuance Costs, Gross	$ 29

Acquisitions (Narrative) (Detai

Acquisitions (Narrative) (Details) $ in Millions	Oct. 02, 2015USD ($)country	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Jun. 30, 2016USD ($)
Business Acquisition [Line Items]
Cash paid for acquisitions, net of cash acquired		$ 9	$ 1,399
Goodwill		7,261		$ 7,167
Goodwill, Acquired During Period		95
Cordis
Business Acquisition [Line Items]
Cash paid for acquisitions, net of cash acquired	$ 1,900
Number of countries in which the entity operates | country	50
Number of principal countries | country	20
Transaction and integration costs		14	$ 21
Goodwill		943
Goodwill, Acquired During Period		82
naviHealth
Business Acquisition [Line Items]
Goodwill		334
Harvard Drug
Business Acquisition [Line Items]
Goodwill		$ 634

Restructuring and Employee Se34

Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Restructuring Charges [Abstract]
Employee-related costs	$ 7	$ 6
Facility exit and other costs	2	6
Total restructuring and employee severance	$ 9	$ 12

Restructuring and Employee Se35

Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) $ in Millions	3 Months Ended
	Sep. 30, 2016USD ($)
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 16
Additions	6
Payments and other adjustments	(5)
Ending Balance	17
Employee- Related Costs
Restructuring Reserve [Roll Forward]
Beginning Balance	15
Additions	6
Payments and other adjustments	(4)
Ending Balance	17
Facility Exit and Other Costs
Restructuring Reserve [Roll Forward]
Beginning Balance	1
Additions	0
Payments and other adjustments	(1)
Ending Balance	$ 0

Goodwill and Other Intangible36

Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) $ in Millions	3 Months Ended
	Sep. 30, 2016USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 7,167
Goodwill acquired, net of purchase price adjustments	95
Foreign currency translation adjustments and other	(1)
Ending balance	7,261
Pharmaceutical
Goodwill [Roll Forward]
Beginning balance	2,919
Goodwill acquired, net of purchase price adjustments	9
Foreign currency translation adjustments and other	(2)
Ending balance	2,926
Medical
Goodwill [Roll Forward]
Beginning balance	4,248
Goodwill acquired, net of purchase price adjustments	86
Foreign currency translation adjustments and other	1
Ending balance	$ 4,335

Goodwill and Other Intangible37

Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2016	Jun. 30, 2016
Indefinite-lived Intangible Assets [Line Items]
Net Intangible	$ 70	$ 72
Finite-Lived Intangible Assets [Line Items]
Gross Intangible	3,270	3,262
Accumulated Amortization	1,174	1,075
Net Intangible	$ 2,096	2,187
Weighted- Average Remaining Amortization Period (Years)	10 years
Gross Intangible, Total other intangible assets	$ 3,340	3,334
Net Intangible, Total other intangible assets	2,166	2,259
IPR&D, trademarks and other
Indefinite-lived Intangible Assets [Line Items]
Net Intangible	70
IPR&D, trademarks and other
Indefinite-lived Intangible Assets [Line Items]
Net Intangible		72
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Intangible	1,931	1,946
Accumulated Amortization	793	737
Net Intangible	$ 1,138	1,209
Weighted- Average Remaining Amortization Period (Years)	9 years
Trademarks, trade names, and patents
Finite-Lived Intangible Assets [Line Items]
Gross Intangible	$ 527	508
Accumulated Amortization	156	140
Net Intangible	$ 371	368
Weighted- Average Remaining Amortization Period (Years)	14 years
Developed technology and other
Finite-Lived Intangible Assets [Line Items]
Gross Intangible	$ 812	808
Accumulated Amortization	225	198
Net Intangible	$ 587	$ 610
Weighted- Average Remaining Amortization Period (Years)	8 years

Goodwill and Other Intangible38

Goodwill and Other Intangible Assets (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 101	$ 67
Estimated annual amortization of intangible assets - 2017	285
Estimated annual amortization of intangible assets - 2018	350
Estimated annual amortization of intangible assets - 2019	281
Estimated annual amortization of intangible assets - 2020	254
Estimated annual amortization of intangible assets - 2021	$ 207

Available-for-Sale Securities39

Available-for-Sale Securities (Schedule of Available-for-Sale Securities) (Details) - USD ($) $ in Millions	Sep. 30, 2016	Jun. 30, 2016
Schedule of Available-for-sale Securities [Line Items]
Total current available-for-sale securities	$ 108	$ 113
Total long-term available-for-sale securities	92	87
Total available-for-sale securities		200
Treasury bills
Schedule of Available-for-sale Securities [Line Items]
Total current available-for-sale securities	0	3
Total long-term available-for-sale securities	29	10
International bonds
Schedule of Available-for-sale Securities [Line Items]
Total current available-for-sale securities	3	2
Total long-term available-for-sale securities	3	1
Corporate bonds
Schedule of Available-for-sale Securities [Line Items]
Total current available-for-sale securities	58	58
Total long-term available-for-sale securities	32	36
U.S. agency bonds
Schedule of Available-for-sale Securities [Line Items]
Total current available-for-sale securities	7	6
Total long-term available-for-sale securities	8	9
Asset-backed securities
Schedule of Available-for-sale Securities [Line Items]
Total current available-for-sale securities	31	28
Total long-term available-for-sale securities	8	17
International equity securities
Schedule of Available-for-sale Securities [Line Items]
Total current available-for-sale securities	2	2
U.S. agency mortgage-backed securities
Schedule of Available-for-sale Securities [Line Items]
Total current available-for-sale securities	7	14
Total long-term available-for-sale securities	$ 12	$ 14

Available-for-Sale Securities40

Available-for-Sale Securities (Narrative) (Details)	3 Months Ended
	Sep. 30, 2016
Short Term
Schedule of Available-for-sale Securities [Line Items]
Weighted average effective maturity	6 months
Long Term
Schedule of Available-for-sale Securities [Line Items]
Weighted average effective maturity	17 months

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($)	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016
Income Taxes
Effective Income Tax Rate Reconciliation, Percent	37.30%	32.30%
Net unfavorable/(favorable) discrete items, amount	$ (28,000,000)
Unrecognized tax benefits	532,000,000		$ 527,000,000
Unrecognized tax benefits that would impact effective tax rate	358,000,000		355,000,000
Unrecognized tax benefits, interest and penalties accrued	149,000,000		145,000,000
Amount CareFusion is liable under tax matters agreement in the event amount must be paid to the taxing authority	126,000,000		$ 172,000,000
Minimum
Income Taxes
Estimated range of decrease in unrecognized tax benefits within the next 12 months	0
Maximum
Income Taxes
Estimated range of decrease in unrecognized tax benefits within the next 12 months	$ 175,000,000
Federal | Minimum
Income Taxes
Tax years open for examination	2,006
Federal | Maximum
Income Taxes
Tax years open for examination	2,016
State and Local | Minimum
Income Taxes
Tax years open for examination	2,006
State and Local | Maximum
Income Taxes
Tax years open for examination	2,016
Foreign | Minimum
Income Taxes
Tax years open for examination	2,006
Foreign | Maximum
Income Taxes
Tax years open for examination	2,016

Commitments, Contingent Liabi42

Commitments, Contingent Liabilities and Litigation (Details) $ in Millions	Oct. 31, 2016plaintifflawsuit	Jul. 31, 2014	Sep. 30, 2016USD ($)	Jun. 30, 2016USD ($)
Subsequent Event
Loss Contingencies [Line Items]
Number of lawsuits filed | lawsuit	31
Number of plaintiffs | plaintiff	250
DEA Investigation and Related Matters
Loss Contingencies [Line Items]
Litigation accrual			$ 44	$ 44
CVS Health
Loss Contingencies [Line Items]
Initial term of pharmaceutical sourcing venture		10 years
Maximum quarterly payment			$ 45.6

Fair Value Measurements (Fair V

Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) - USD ($) $ in Millions	Sep. 30, 2016	Jun. 30, 2016
Assets:
Total available-for-sale securities		$ 200
Recurring
Assets:
Cash equivalents	$ 176	516
Forward contracts	2	19
Total available-for-sale securities	200	200
Other investments	109	103
Liabilities:
Contingent Consideration	(21)	(19)
Recurring | Level 1
Assets:
Cash equivalents	176	516
Forward contracts	0	0
Total available-for-sale securities	0	0
Other investments	109	103
Liabilities:
Contingent Consideration	0	0
Recurring | Level 2
Assets:
Cash equivalents	0	0
Forward contracts	2	19
Total available-for-sale securities	200	200
Other investments	0	0
Liabilities:
Contingent Consideration	0	0
Recurring | Level 3
Assets:
Cash equivalents	0	0
Forward contracts	0	0
Total available-for-sale securities	0	0
Other investments	0	0
Liabilities:
Contingent Consideration	$ (21)	$ (19)

Fair Value Measurements (Reconc

Fair Value Measurements (Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis Using Unobservable Inputs (Level 3)) (Details) - Recurring - Contingent Consideration Obligation $ in Millions	3 Months Ended
	Sep. 30, 2016USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at beginning of period	$ 19
Additions from acquisitions	2
Changes in fair value of contingent consideration	0
Balance at end of period	$ 21

Financial Instruments (Narrativ

Financial Instruments (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Derivative [Line Items]
Payments for (Proceeds from) Hedge, Financing Activities	$ (14)	$ 0
Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swap
Derivative [Line Items]
Derivative, notional amount	200
Derivatives, terminated notional amounts	$ 200

Financial Instruments (Summary

Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details) - USD ($) $ in Millions	Sep. 30, 2016	Jun. 30, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying amount	$ 5,532	$ 5,539
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Estimated fair value	$ 5,884	$ 5,780

Redeemable Noncontrolling Int47

Redeemable Noncontrolling Interests (Narrative) (Details)	Sep. 30, 2016
naviHealth
Redeemable Noncontrolling Interest [Line Items]
Ownership interest (as a percent)	82.00%

Redeemable Noncontrolling Int48

Redeemable Noncontrolling Interests (Changes in Redeemable Noncontrolling Interests) (Details) $ in Millions	3 Months Ended
	Sep. 30, 2016USD ($)
Increase (Decrease) in Temporary Equity [Roll Forward]
Balance at beginning of period	$ 117
Balance at end of period	116
naviHealth
Increase (Decrease) in Temporary Equity [Roll Forward]
Balance at beginning of period	117
Net earnings attributable to redeemable noncontrolling interests	1
Net purchase of redeemable noncontrolling interests	(2)
Balance at end of period	$ 116

Shareholders' Equity (Narrative

Shareholders' Equity (Narrative) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Class of Stock [Line Items]
Treasury Stock, Value, Acquired, Cost Method		$ 0
Treasury Shares
Class of Stock [Line Items]
Treasury shares acquired (using cost method), shares	3
Treasury shares acquired, average price per share (in usd per share)	$ 81.37

Shareholders' Equity (Changes i

Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
AOCI, Net of Tax [Roll Forward]
Balance at beginning of period	$ 6,571
Other comprehensive income/(loss), before reclassifications	1
Amounts reclassified to earnings	(1)
Total other comprehensive income/(loss), net of tax	0	$ (45)
Balance at end of period	6,531
Foreign Currency Translation Adjustments
AOCI, Net of Tax [Roll Forward]
Balance at beginning of period	(123)
Other comprehensive income/(loss), before reclassifications	(1)
Amounts reclassified to earnings	0
Total other comprehensive income/(loss), net of tax	(1)
Balance at end of period	(124)
Unrealized Gain/(Loss) on Derivatives, net of tax
AOCI, Net of Tax [Roll Forward]
Balance at beginning of period	7
Other comprehensive income/(loss), before reclassifications	2
Amounts reclassified to earnings	(1)
Total other comprehensive income/(loss), net of tax	1
Balance at end of period	8
Accumulated Other Comprehensive Loss
AOCI, Net of Tax [Roll Forward]
Balance at beginning of period	(116)
Balance at end of period	$ (116)

Earnings Per Share Attributab51

Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) - shares shares in Millions	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Earnings Per Share [Abstract]
Weighted-average common shares–basic (in shares)	320	328
Effect of dilutive securities:
Employee stock options, restricted share units, and performance share units (in shares)	2	3
Weighted-average common shares–diluted (in shares)	322	331

Earnings Per Share Attributab52

Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details) - shares shares in Millions	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Earnings Per Share [Abstract]
Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)	3	2

Segment Information (Narrative)

Segment Information (Narrative) (Details) $ in Millions	3 Months Ended
	Sep. 30, 2016USD ($)segment	Sep. 30, 2015USD ($)
Segment Reporting [Abstract]
Number of operating segments	2
Number of reportable segments	2
Project costs on investment and other spending | $	$ 1	$ 6

Segment Information (Revenue by

Segment Information (Revenue by Reportable Segment) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting Information [Line Items]
Total revenue	$ 32,039	$ 28,055
Operating Segments
Segment Reporting Information [Line Items]
Total revenue	32,041	28,059
Operating Segments | Pharmaceutical
Segment Reporting Information [Line Items]
Total revenue	28,762	25,140
Operating Segments | Medical
Segment Reporting Information [Line Items]
Total revenue	3,279	2,919
Corporate
Segment Reporting Information [Line Items]
Total revenue	$ (2)	$ (4)

Segment Information (Segment Pr

Segment Information (Segment Profit by Reportable Segment) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating earnings	$ 535	$ 620
Operating Segments
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating earnings	661	758
Operating Segments | Pharmaceutical
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating earnings	534	657
Operating Segments | Medical
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating earnings	127	101
Corporate
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating earnings	$ (126)	$ (138)

Segment Information (Assets by

Segment Information (Assets by Reportable Segment) (Details) - USD ($) $ in Millions	Sep. 30, 2016	Jun. 30, 2016
Segment Reporting Information [Line Items]
Total assets	$ 34,406	$ 34,122
Operating Segments | Pharmaceutical
Segment Reporting Information [Line Items]
Total assets	21,034	20,662
Operating Segments | Medical
Segment Reporting Information [Line Items]
Total assets	10,553	10,236
Corporate
Segment Reporting Information [Line Items]
Total assets	$ 2,819	$ 3,224

Share-Based Compensation (Narra

Share-Based Compensation (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Tax benefit related to share-based compensation	$ 8	$ 11
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	3 years
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 35
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years
Stock Options | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable period of plans (in years)	7 years
Stock Options | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable period of plans (in years)	10 years
Restricted Share Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	3 years
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 121
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years
Performance Share Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	3 years
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 23
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years
Performance Share Units | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Target performance goal (as a percent)	0.00%
Performance Share Units | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Target performance goal (as a percent)	200.00%

Share-Based Compensation (Sched

Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation	$ 23	$ 30
Restricted Share Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation	17	13
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation	5	5
Performance Share Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation	$ 1	$ 12

Share-Based Compensation (Sch59

Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details) shares in Millions	3 Months Ended
	Sep. 30, 2016$ / sharesshares
Stock Options
Outstanding at beginning of period (in shares) | shares	7
Granted (in shares) | shares	2
Exercised (in shares) | shares	(1)
Canceled and forfeited (in shares) | shares	0
Outstanding at end of period (in shares) | shares	8
Exercisable at end of period (in shares) | shares	5
Weighted-Average Exercise Price per Common Share
Outstanding at beginning of period (in usd per share) | $ / shares	$ 54.09
Granted (in usd per share) | $ / shares	83.14
Exercised (in usd per share) | $ / shares	37.83
Canceled and forfeited (in usd per share) | $ / shares	0
Outstanding at end of period (in usd per share) | $ / shares	60.65
Exercisable at end of period (in usd per share) | $ / shares	$ 49.96

Share-Based Compensation (Sch60

Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details) - Stock Options - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value of outstanding options at period end	$ 147	$ 181
Aggregate intrinsic value of exercisable options at period end	$ 145	$ 161
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	7 years	6 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	6 years	5 years

Share-Based Compensation (Sch61

Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) - Restricted Share Units shares in Millions	3 Months Ended
	Sep. 30, 2016$ / sharesshares
Restricted Share Units
Nonvested at beginning of period (in shares) | shares	2
Granted (in shares) | shares	1
Vested (in shares) | shares	(1)
Canceled and forfeited (in shares) | shares	0
Nonvested at end of period (in shares) | shares	2
Weighted-Average Grant Date Fair Value per Share
Nonvested at beginning of period (in usd per share) | $ / shares	$ 71.73
Granted (in usd per share) | $ / shares	83.15
Vested (in usd per share) | $ / shares	68.14
Canceled and forfeited (in usd per share) | $ / shares	0
Nonvested at end of period (in usd per share) | $ / shares	$ 80.22

Share-Based Compensation (Sch62

Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) - Performance Share Units shares in Millions	3 Months Ended
	Sep. 30, 2016$ / sharesshares
Performance Share Units
Nonvested at beginning of period (in shares) | shares	0.8
Granted (in shares) | shares	0.2
Vested (in shares) | shares	(0.4)	[1]
Canceled and forfeited (in shares) | shares	0
Nonvested at end of period (in shares) | shares	0.6
Weighted-Average Grant Date Fair Value per Share
Nonvested at beginning of period (in usd per share) | $ / shares	$ 63.96
Granted (in usd per share) | $ / shares	83.19
Vested (in usd per share) | $ / shares	51.49
Canceled and forfeited (in usd per share) | $ / shares	0
Nonvested at end of period (in usd per share) | $ / shares	$ 77.72
[1]	Vested based on achievement of 170 percent of the target performance goal.